BridgeBio raises $300 million through partial capped monetization of BEYONTTRA European royalty

1 week ago 2

BridgeBio Pharma (NASDAQ:BBIO) announced on Monday it has sold a portion of royalties due to the company from sales of BEYONTTRA in Europe to HealthCare Royalty and funds managed by Blue Owl Capital (NYSE:OWL) for $300 million.
The company said

Recommended For You

More Trending News

Read Entire Article